Trial · NCT05792761
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate. | 24 weeks after completing treatment. | Defined as the proportion of child patients with HBsAg \< 0.05 IU / mL (or below the lower detection limit) 24 weeks after completing treatment, HBeAg negative, HBV DNA undetectable, and normalization of liver biochemical indexes (ALT and AST). |
| Secondary | Proportion of patients with HBV-DNA negative in those with HBV-DNA positive at baseline. | 24 weeks after treatment completion | Defined as HBV-DNA below the lower detection limit, or\< 20 IU/mL. |
| Secondary | HBeAg seroconversion rate in HBeAg positive children. | 24 weeks after treatment completion. | Defined as HBeAg negative and anti-HBe positive. |
| Secondary | HBsAg seroconversion rate. | 24 weeks after treatment completion. | Defined as HBsAg \< 0.05 IU/mL and anti-HBe positive. |
| Secondary | ALT normalization rate. | 48 weeks and 96 weeks after starting treatment | |
| Secondary | Decrease of HBV-DNA compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | Decrease of HBeAg compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | Decrease of HBsAg compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | The incidence of adverse reactions. | 24weeks ,48 weeks and 96 weeks after starting treatment | Including fever, influenza-like symptoms, decreased hemogram, jaundice ALT\> 400U/L, abnormal renal function, abnormal thyroid function, abnormal blood phosphorus and blood calcium during treatment (lower or higher than the normal value). |
| Secondary | The effects on height | 24weeks ,48 weeks and 96 weeks after starting treatment | |
| Secondary | The effects on weight | 24weeks ,48 weeks and 96 weeks after starting treatment | |
| Secondary | The effects on bone age. | 24weeks ,48 weeks and 96 weeks after starting treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05792761/registered